Hematologist Arthur Nienhuis named 2009 ASH Mentor Award recipient

November 02, 2009

Arthur Nienhuis, M.D., of St. Jude Children's Research Hospital, is the recipient of the 2009 Mentor Award from the American Society of Hematology (ASH). Nienhuis will receive the honor at the society's annual meeting this December in New Orleans.

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The Mentor Award recognizes hematologists who have excelled at mentoring trainees and colleagues. Award recipients are chosen because they have shown a sustained commitment to mentoring; have made a significant, positive impact on their mentees' careers; and have advanced research and patient care in the field of hematology through those they train.

Two awards are given each year--one in the basic sciences and one to an outstanding clinical investigator mentor. Nienhuis will receive the award for clinical investigation.

"Dr. Nienhuis' dedication and attention to those he mentors has molded a new generation of researchers, and his passion for helping shape junior and senior faculty continues today," said Dr. William E. Evans, St. Jude director and CEO. "His long-standing commitment to trainees and colleagues has prepared many of today's leaders in hematology around the world."

Nienhuis' expertise in bone marrow transplantation, gene therapy and genetic testing paved the way for many advances at St. Jude, including breakthroughs in sickle cell disease and other hematological disorders. He also made significant achievements in the fields of cell therapy, HIV/AIDS research and inherited immunodeficiencies. Through his work, Nienhuis improved care for patients, while helping other researchers carry on the fight against catastrophic childhood disease.

Nienhuis has received numerous honors, including being named to the National Cancer Advisory Board by former President Bill Clinton in 1998. That same year, Nienhuis was awarded the Stratton Medal by ASH, one of the society's highest honors for an outstanding body of work in hematology. In 2002, he was elected to the Institute of Medicine of the National Academy of Sciences. Nienhuis served as fourth director and CEO of St. Jude from 1993 to 2004.
St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

St. Jude Children's Research Hospital

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.